Tensegrity Pharma and argenx Collaborate on Innovative TSP-101 Research
Tensegrity Pharma and argenx Join Forces
In a groundbreaking partnership announced recently, Tensegrity Pharma, a Tokyo-based startup, has formally entered into a collaboration with argenx BV, a global leader in the field of immune diseases. This new partnership focuses on the joint research and development of TSP-101, Tensegrity Pharma's innovative drug candidate aimed at treating various inflammatory and immune disorders.
This agreement signifies a close collaboration between Tensegrity Pharma and argenx, as both companies will work together on non-clinical and clinical trials, as well as other related development activities for TSP-101. The partnership aims to rigorously evaluate the scientific value and clinical potential of TSP-101, focusing on muscle wasting conditions and a wide range of inflammatory and immune diseases.
TSP-101 is notable for being Tensegrity Pharma's first fully human monoclonal antibody that specifically targets Fn14. This cutting-edge drug candidate aims to control a variety of inflammatory diseases by inhibiting Fn14 signaling, which is particularly relevant in conditions like cachexia associated with cancer. TSP-101 is supported by the Japan Agency for Medical Research and Development (AMED) through its Drug Venture Ecosystem Enhancement Project, specifically focusing on the development of new treatments for cachexia in cancer patients.
The expertise of argenx in immunology and antibody drug development is expected to significantly accelerate the progress of TSP-101. With argenx's extensive track record in the field, this collaboration is seen as a vital step towards bringing this promising drug to market.
About Tensegrity Pharma
Tensegrity Pharma is an innovative startup founded on the principle of resolving bottlenecks in the drug development pipeline globally. The company focuses on evaluating and recapturing drug candidates that have been strategically discontinued in development, aiming to realize their potential value through exploratory clinical trials on a global scale. The ultimate goal is to advance these discoveries toward partnerships with pharmaceutical companies or pursue mergers and acquisitions.
- - CEO: Takuto Nakahara
- - Location: 7F Nihonbashi Mizuno Building, 1-11-12 Nihonbashi Muromachi, Chuo-Ku, Tokyo, 103-0022
- - Established: March 7, 2023
- - Website: Tensegrity Pharma
About argenx BV
Argenx BV is a global biopharmaceutical company that focuses on improving the lives of individuals suffering from severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx collaborates with leading academic researchers to translate groundbreaking scientific discoveries in immunology into a world-class portfolio of innovative antibody therapies. The company has successfully developed and commercialized the world's first approved drug targeting the fetal Fc receptor (FcRn), and is currently assessing a variety of treatment options for multiple severe autoimmune diseases.
- - CEO: Tim Van Hauwermeiren
- - Location: Industriepark-Zwijnaarde 7, 9052 Zwijnaarde, Belgium
- - Established: 2008
- - Website: argenx
Contact Information
For inquiries regarding this collaboration, please reach out to Tensegrity Pharma's Public Relations department at [email protected].
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.